Analysts Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Price Target at $27.29

by · The Cerbat Gem

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $27.2857.

Several equities research analysts have recently weighed in on KALV shares. JMP Securities boosted their target price on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Friday, September 12th. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 4th. Citizens Jmp reduced their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th.

Check Out Our Latest Analysis on KalVista Pharmaceuticals

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $15.80 on Monday. The firm has a market cap of $798.44 million, a price-to-earnings ratio of -4.00 and a beta of -0.14. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The business’s 50 day moving average is $13.44 and its two-hundred day moving average is $13.35. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $17.30.

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last issued its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million during the quarter, compared to the consensus estimate of $6.03 million. Analysts forecast that KalVista Pharmaceuticals will post -3.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Paul K. Audhya sold 5,296 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider directly owned 131,831 shares of the company’s stock, valued at approximately $1,773,126.95. The trade was a 3.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Brian Piekos sold 4,471 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $60,134.95. Following the sale, the chief financial officer directly owned 10,529 shares of the company’s stock, valued at approximately $141,615.05. This represents a 29.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 31,329 shares of company stock valued at $437,371 over the last 90 days. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of KALV. The Manufacturers Life Insurance Company raised its stake in shares of KalVista Pharmaceuticals by 5.9% during the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock valued at $165,000 after purchasing an additional 818 shares in the last quarter. BNP Paribas Financial Markets grew its position in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares in the last quarter. Rhumbline Advisers increased its stake in KalVista Pharmaceuticals by 2.8% during the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock valued at $615,000 after buying an additional 1,458 shares during the period. Police & Firemen s Retirement System of New Jersey raised its position in shares of KalVista Pharmaceuticals by 26.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock worth $110,000 after buying an additional 2,061 shares in the last quarter. Finally, Corebridge Financial Inc. raised its position in shares of KalVista Pharmaceuticals by 12.7% during the 1st quarter. Corebridge Financial Inc. now owns 19,094 shares of the specialty pharmaceutical company’s stock worth $220,000 after buying an additional 2,149 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

(Get Free Report)

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.

See Also